

Declaration of Interests Register

TA Committee D

Publication Date: 14/08/2019

Topic: Dacomitinib for untreated EGFR-positive non-small-cell lung cancer [ID1346]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
<i>Carol Davies</i>	<i>Patient Expert</i>	<i>Indirect financial interest</i>	<i>National Lung Cancer Forum for Nurses (NLCFN) had received educational sponsorship from pharmaceutical companies.</i>				<i>It was agreed that this declaration would not prevent Carol Davies from participating in this section of the meeting</i>
<i>Alistair Greystoke</i>	<i>Clinical Expert</i>	<i>Direct financial interest</i>	<i>Received speaker and consultancy fees from AstraZeneca, Pfizer, Roche and Boehringer</i>				<i>It was agreed that this declaration would not prevent Alistair Greystoke from participating in this section of the meeting</i>